重组截短脑膜炎奈瑟菌巨噬细胞感染增强蛋白(rT-Nm-MIP)免疫诱导小鼠抗体对淋病奈瑟菌交叉反应并具杀菌活性
本研究制备含重组截短脑膜炎奈瑟菌巨噬细胞感染增强蛋白(rT-Nm-MIP,氨基酸22-142)的脂质体(n=3)及脂质体+单磷酸酰脂质A(MPLA)(n=3)批次,免疫小鼠后检测抗原性与杀菌活性。各批次抗原性无显著差异(P>0.05);抗血清可识别脑膜炎奈瑟菌与淋病奈瑟菌的MIP,并对部分脑膜炎奈瑟菌B群及淋病奈瑟菌株产生补体依赖性杀菌活性。作者认为需含多种Nm/Ng-MIP型蛋白的多组分疫苗才能覆盖两种病原体。
要点
- rT-Nm-MIP脂质体±MPLA批次间抗原性无显著差异(P>0.05)。
- 抗M2 rT-Nm-MIP血清可识别Nm-MIP与Ng-MIP,对Δmip菌无反应。
- 抗血清对部分MenB及淋病奈瑟菌株有杀菌活性,对MenA、MenY及FA1090无杀菌。
核心结论
- 含rT-Nm-MIP的脂质体±MPLA疫苗批次间抗原性一致,诱导的抗体可交叉识别Nm与Ng的MIP并对部分菌株产生杀菌活性。
- 作者认为需含多种Nm/Ng-MIP型蛋白的多组分疫苗才能广泛覆盖两种病原体。
研究设计与样本
- 制备独立批次的脂质体(n=3)及脂质体+MPLA(n=3),内含重组截短Nm-MIP(Allele 2编码,氨基酸22-142),免疫小鼠。
- 检测批次间抗原性,并用抗血清进行全菌识别与人体补体/血清杀菌试验。
- 另尝试改造Nm外膜表达M2截短Nm-MIP,但用Na-DOC提取脂寡糖被禁忌。
主要发现
- 不同批次M2 rT-Nm-MIP脂质体±MPLA抗原性无显著批次间差异(P>0.05)。
- 抗rT-Nm-MIP血清与Nm-MIP及Ng-MIP在外膜和活菌表面反应相同且特异,与Δmip菌无反应。
- 抗M2 rT-Nm-MIP血清对同源MenB株杀菌中位滴度:脂质体组32-64,脂质体+MPLA组128-256;对异源表达M1蛋白MenB株:脂质体组64,脂质体+MPLA组128-256。
- 对表达M7蛋白MenB分离株低水平杀菌(P<0.05,滴度4-8),对表达M6蛋白MenB株无杀菌(滴度<4-8)。
- 对表达同源M2蛋白MenC和MenW有杀菌(P<0.05,滴度8-16),对MenA或MenY无杀菌(滴度<4-8)。
关键数值与推荐
- 同源MenB杀菌中位滴度:抗rT-Nm-MIP脂质体血清32-64,抗rT-Nm-MIP脂质体+MPLA血清128-256。
- 异源表达M1蛋白MenB杀菌滴度:抗rT-Nm-MIP脂质体血清64,抗rT-Nm-MIP脂质体+MPLA血清128-256。
- 表达M7蛋白MenB分离株杀菌滴度4-8(P<0.05);表达M6蛋白MenB株滴度<4-8(无杀菌)。
- MenC和MenW(表达同源M2蛋白)杀菌滴度8-16(P<0.05);MenA或MenY滴度<4-8(无杀菌)。
- 淋病奈瑟菌P9-17(M35 Ng-MIP)杀菌滴度64-512(P<0.05);12CFX_T_003(M10 Ng-MIP)滴度8-16;FA1090(M8 Ng-MIP)无杀菌。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Neisseria meningitidis (Nm) and N. gonorrhoeae (Ng) express a Macrophage Infectivity Potentiator (MIP, NMB1567/NEIS1487) protein in their outer membrane (OM). In this study, we prepared independent batches of liposomes (n = 3) and liposomes + MonoPhosphoryl Lipid A (MPLA) (n = 3) containing recombinant truncated Nm-MIP protein encoded by Allele 2 (rT-Nm-MIP, amino acids 22-142), and used these to immunize mice. We tested the hypothesis that independent vaccine batches showed similar antigenicity, and that antisera could recognise both meningococcal and gonococcal MIP and induce cross-species bactericidal activity. The different batches of M2 rT-Nm-MIP-liposomes ± MPLA showed no significant (P > 0.05) batch-to-batch variation in antigenicity. Anti-rT-Nm-MIP sera reacted equally and specifically with Nm-MIP and Ng-MIP in OM and on live bacterial cell surfaces. Specificity was shown by no antiserum reactivity with Δmip bacteria. Using human complement/serum bactericidal assays, anti-M2 rT-Nm-MIP sera killed homologous meningococcal serogroup B (MenB) strains (median titres of 32-64 for anti-rT-Nm-MIP-liposome sera; 128-256 for anti-rT-Nm-MIP-liposome + MPLA sera) and heterologous M1 protein-expressing MenB strains (titres of 64 for anti rT-Nm-MIP-liposome sera; 128-256 for anti-rT-Nm-MIP-liposome + MPLA sera). Low-level killing (P < 0.05) was observed for a MenB isolate expressing M7 protein (titres 4-8), but MenB strains expressing M6 protein were not killed (titre < 4-8). Killing (P < 0.05) was observed against MenC and MenW bacteria expressing homologous M2 protein (titres of 8-16) but not against MenA or MenY bacteria (titres < 4-8). Antisera to M2 rT-Nm-MIP showed significant (P < 0.05) cross-bactericidal activity against gonococcal strain P9-17 (expressing M35 Ng-MIP, titres of 64-512) and strain 12CFX_T_003 (expressing M10 Ng-MIP, titres 8-16) but not against FA1090 (expressing M8 Ng-MIP). As an alternative to producing recombinant protein, we engineered successfully the Nm-OM to express M2 Truncated-Nm-MIP, but lipooligosaccharide-extraction with Na-DOC was contra-indicated. Our data suggest that a multi-component vaccine containing a select number of Nm- and Ng-MIP type proteins would be required to provide broad coverage of both pathogens.
引用
- Humbert MV, Christodoulides M. Immunization with recombinant truncated Neisseria meningitidis-Macrophage Infectivity Potentiator (rT-Nm-MIP) protein induces murine antibodies that are cross-reactive and bactericidal for Neisseria gonorrhoeae. Vaccine. 2018. PMID: 29803329. doi:10.1016/j.vaccine.2018.05.069
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。